The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zenkov L.R.

Klinika nervnykh bolezneĭ im. A.Ia. Kozhevnikova;
laboratoriia kliniko-élektrofiziologicheskikh issledovaniĭ Pervogo MGMU im. I.M. Sechenova

Antiepileptic drug lacosamide (vimpat)

Authors:

Zenkov L.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(10): 72‑79

Read: 9266 times

Download PDF (RU)
Contact the author
Table of contents

ANTIEPILEPTIC DRUG LACOSAMIDE (VIMPAT)
ANTIEPILEPTIC DRUG LACOSAMIDE (VIMPAT)

To cite this article:

Zenkov LR. Antiepileptic drug lacosamide (vimpat). S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(10):72‑79. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Brain microstructural abno­rmalities asse­ssed by diffusion kurtosis MRI in patients with focal temporal lobe epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):171-177
Stereo-EEG-guided radiofrequency thermocoagulations in drug-resistant focal epilepsy. Burdenko's Journal of Neurosurgery. 2025;(3):7-16
Abstract:

Keywords:

lacosamid
focal epilepsy

Authors:

Zenkov L.R.

Klinika nervnykh bolezneĭ im. A.Ia. Kozhevnikova;
laboratoriia kliniko-élektrofiziologicheskikh issledovaniĭ Pervogo MGMU im. I.M. Sechenova

Close metadata

References:

  1. Gekht A.B., Mil'chakova L.E., Churilin Yu.Yu. i dr.Epidemiologiya epilepsii v Rossii. Zhurn nevrol i psikhiat (Prilozhenie 1) 2006; 106: 3-7.
  2. Zenkov L.R.Vybor preparata v lechenii fokal'nykh epilepsii: mesto val'proatov. Rus med zhurn 2009; 17: 20: 1334-1340.
  3. Andurkar S.V., Beguin C., Stables J.P., Kohn H.Synthesis and structural studies of aza analogues of functionalized amino acids: new anticonvulsant agents. J Med Chem 2001; 44: 1475-1478.
  4. Barton M.E., Klein B.D., Wolf H.H., White Brock M.Pharmacological characterization of 6 Hz psychomotor seizure model of partial epilepsy. Epilep Res 2001; 47: 217-227.
  5. Bauer S., Rudd David G., Mylius V. et al.Lacosamide intoxication in attempted suicide. Epilep Behav 2010; 17: 549-551.
  6. Bee L.A., Dickenson A.H.Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy. Neuropharmacology 2009; 57: 472-479.
  7. Ben-Menachem E.Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008; 44: 35-40.
  8. Beydoun A., D'Souza J., Hebert D., Doty P.Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009; 9: 33-42.
  9. Beyreuther B.K., Freitag J., Heers C. et al.Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13: 21-42.
  10. Biton V., Rosenfeld W.E., Whitesides J. et al.Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49: 418-424.
  11. Brandt C., Heile A., Potschka H. et al.Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006; 47: 1803-1809.
  12. Cawello W., Keopeit D., Schiltmeyer B. et al.Food does not affect the pharmacokinetica of SPM 927. Epilepsia 2004; 45: Suppl 7: 307.
  13. Cawello W., Nickel B., Eggert-Formella A.No Pharmacokinetic Interaction Between Lacosamide and Carbamazepine in Healthy Volunteers. J Clin Pharmacol 2010; 50: 459-471.
  14. Chung S.S., Sperling M., Biton V. et al.Lasosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 2007; 48: Suppl 6: 321.
  15. Chung S.S.New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Advanc Neurol Dis 2010; 3: 77-83.
  16. Cross S.A., Curran M.P.Lacosamide: in partial-onset seizures. Drugs 2009; 69: 449-459.
  17. Curia G., Biagini G., Perucca E., Avoli M.Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009; 23: 555-568.
  18. de la Loge C., Cramer J., Borghs S. et al.Improvement in patient-reported outcomes in patients responding to lacosamide: pooled QOLIE-31, SSS and PGIC data from three phase II/III clinical trials. 28th International Epilepsy Congress, 29.06-02.07.09. Poster presentation 2009.
  19. Duncan G.E., Kohn H.The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilep Res 2005; 67: 81-87.
  20. Errington A.C., Stöhr T., Heers C., Lees G.The Investigational Anticonvulsant Lacosamide Selectively Enhances Slow Inactivation of Voltage-Gated Sodium Channels. Mol Pharmacol 2008; 73: 157-169.
  21. Fountain N.B., French J.A., Privitera M.D.Harkoseride: safety and tolerability of a new antiepileptic drug (AED) in patients with refractory partial seizures. Epilepsia 2000; 41: Suppl 7: 169-170.
  22. French J., Brodie M., Hebert D. et al.Evaluation of seizure freedom and 75% responder rates with lacosamide in subjects with partial-onset seizures in phase II/III clinical trials. 28th International Epilepsy Congress, 29.06-02.07.09. Poster presentation 2009.
  23. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M. et al.and SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-453.
  24. Hao J.X., Stohr T., Selve N. et al.A new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol 2006; 553: Lacosamide 1-3: 135-140.
  25. Harris J.A., Murphy J.A.Lacosamide: An adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009; 43: 1809-1817.
  26. Hashimoto K., Fukushima T., Shimizu E. et al.Possible role of D-serine in the pathophysiology of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiat 2004; 28: 385-388.
  27. Higgins G.A., Breysse N., Undzys E. et al.Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology (Berl) 2010; 207: 513-527.
  28. Higgins G.A., Breysse N., Undzys E. et al.The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents. Eur J Pharmacol 2009; 624: 1-9.
  29. Kehne J.H., Kane J.M., Chaney S.F. et al.Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilep Res 1997; 27: 41-54.
  30. Kellinghaus C.Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009; 5: 757-766.
  31. Kellinghaus C., Berning S., Besselmann M.Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilep Behav 2009; 14: 429-431.
  32. Knake S., Hamer H.M., Rosenow F.Status epilepticus: a critical review. Epilep Behav 2009; 15: 10-14.
  33. Kupferberg H.Animal models used in the screening of antiepileptic drugs. Epilepsia 2001; 42: Suppl 4: 7-12.
  34. Larner A.J.Epileptic seizures in AD patients. Neuromolecular Med 2010; 12: 71-77.
  35. Lees G., Stohr T., Errington A.C.Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro. Neuropharmacology; 2006: 50: 98-110.
  36. Malawska B.New anticonvulsant agents. Curr Top Med Chem 2005; 5: 69-85.
  37. Perucca E.What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 2009; 50: Suppl 12: 49-50.
  38. Rosenow F., Knake S.Review: Recent and future advances in the treatment of status epilepticus. Therapeutic Advances in Neurological Disorders 2008; 25: 32.
  39. Sachdeo R., Montouris G., Beydoun A. et al.An open-label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures. Neurology 2003; 60: Suppl 1: A433.
  40. Shaibani A., Fares S., Selam J.L. et al.Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009; 10: 818-828.
  41. Sheets P.L., Heers C., Stoehr T., Cummins T.R.Differential Block of Sensory Neuronal Voltage-Gated Sodium Channels by Lacosamide [(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide], Lidocaine, and Carbamazepine. J Pharmacol Exp Ther 2008; 326: 89-99.
  42. Stohr T., Krause E., Selve N.Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 2006; 10: 241-249.
  43. Stohr T., Kupferberg H.J., Stables J.P. et al.Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007; 74: 147-154.
  44. Stohr T., Lekieffre D., Freitag J.Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. Eur J Pharmacol 2008; 589: 114-116.
  45. Tilz C., Resch R., Hofer T., Eggers C.Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010; 51: 316-317.
  46. Twardowschy C.A., De Paola L., Germiniani F.M.B. et al.Pearls & Oy-sters: Soft-tissue necrosis as a result of intravenous leakage of phenytoin. Neurology 2009; 73: e94-e95.
  47. Wehner T., Bauer S., Hamer H.M. et al.Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16: 423-425.
  48. White H.S., Johnson M., Wolf H.H., Kupferberg H.J.The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital J Neurol Sci 1995; 16: 73-77.
  49. Wolff C., Errington A., Lees G., Stöhr T.The proposed mode of action of lacosamide. the newly available antiepileptic drug for partial seizures. 28th International Epilepsy Congress, June 29-July 2. 2009.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.